Review

Innovations and Mechanisms in Liposomal Drug Delivery: A Comprehensive Introduction

Ashutosh Sengar *

Posted Date: 3 January 2025

doi: 10.20944/preprints202501.0206.v1

Keywords: liposomes; drug delivery; biocompatibility; encapsulation; targeted therapy

Review

Innovations and Mechanisms in Liposomal Drug Delivery: A Comprehensive Introduction

Ashutosh Sengar *

Assistant Professor, Smt. Vidyawati College of Pharmacy, Jhansi (U. P.), 284002, India; ashutoshsengar26567@gmail.com

Abstract: Liposomal drug delivery systems are one of the most promising innovations to revolutionize this pharmaceutical industry. It incorporates drugs with hydrophilic as well as hydrophobic properties into a biocompatible lipid bilayer. In this review, general properties of liposomes will be discussed, including composition and mechanisms involved in the augmentation of drug solubility, stability, and targeted delivery. It referred to the development of liposomal formulations and important milestones, such as the FDA approval of Doxil, as the turning points in the clinical application of liposomes. It has been used in the therapeutic field of oncology where the systemic toxicity reduces simultaneously while making the therapy more effective. Also emphasized in this paper are the advantages of liposomal systems, sustained release profiles, and combination therapies that can help against the problem of drug resistance. A further review of the current clinical applications of liposomes is advanced in order to show successful products which have, indeed, impacted the treatment of a patient. There's a good scope for the integration of liposomal technology with novel therapeutic strategies and it's in this direction that the mandate of treating more effectively and personalizing treatment may be considered. The review focuses on the critical role of liposomal drug delivery systems in modern medicine, underlining their potential to revolutionize therapeutic approaches and patient outcomes.

Keywords: Liposomes; Drug delivery; Biocompatibility; Encapsulation; Targeted therapy

1. Introduction to Liposomes

1.1. Definition and Structure of Liposomes

It has been said that the drug delivery systems in liposomes are defined more closely in terms of spherical vesicles composed of one or more bilayers of phospholipids enveloping an aqueous core. This structure has been able to present an opportunity to now use liposomes not only for the delivery of drugs having the property of being both lipophilic and hydrophilic but also for improved solubility and bioavailability. According to this, the amphiphilic phospholipid molecules have to form a lipid bilayer with heads facing outwards and tails facing inwards. This will produce stabilization of liposome and capacity for varying kinds of drugs to be carried illicitly within available parts, hence making it an efficient vehicle for drug delivery [1], [2].

The liposomal size range would be approximately 50 nm to larger several micrometers, and thus their pharmacokinetics, distribution, and cellular uptake would differ significantly. Indeed, better tissue penetration and cellular uptake of smaller vesicles and larger liposomes' capability to carry large molecules and sustain circulation in blood are notable advantages. Alteration of surface characteristics such as charge and hydrophilicity may enhance stability and targeting of the liposomes. ***For example,*** PEGylation was found to increase the circulation time of liposomes in the blood and improve the therapeutic effectiveness of the encapsulated drugs [3], [4].

 doi:10.20944/preprints202501.0206.v1

Table 1. Liposome Size and Penetration.

S. No.	Factor	Description	References
1	**Size of Liposomes**	Liposomes range from 50 nm to several micrometers. Size affects pharmacokinetics, distribution, and cellular uptake.	[3], [4]
2	**Tissue Penetration**	Smaller liposomes penetrate tissues more effectively, enhancing cellular uptake.	[3]
3	**Larger Liposomes**	Larger liposomes are better suited for delivering larger molecules or prolonged circulation in the bloodstream.	[4]

Table 2. Surface Characteristics and PEGylation.

S. No.	Factor	Description	References
1	**Surface Characteristics**	Modifying surface characteristics (charge and hydrophilicity) improves stability and targeting.	[3], [4]
2	**PEGylation**	PEG incorporation prolongs circulation time in the bloodstream, enhancing the therapeutic efficacy of drugs.	[3], [4]

1.2. Historical Context

Liposomes were known a long time prior to this: since the very early 1960s. It was demonstrated that phospholipids would spontaneously form bilayer structures within aqueous media; from then, this fact formed the foundation to progress toward liposomal formulation as a delivery vehicle for drugs. The first critical application of liposomes in medicine is the FDA approval of Doxil® liposomal doxorubicin in 1995. The Doxil® demonstrated a superior pharmacokinetic profile with decreased cardiotoxicity compared to its conventional counterpart, doxorubicin, hence holding a good promise for enhanced therapeutic efficiency without adverse effects [5, 6].

Since the approval of Doxil®, many liposomal formulations have been developed and approved for different therapeutic applications. Among these include antifungal agents, antibiotics, and vaccines, which can be classified as falling under research and innovation for liposomal technology. The starting point of a laboratory research toward clinical application has marked the significance of liposomal formulation in modern medicine [7], [8].

1.3. Importance in Modern Medicine

These are considered increasingly significant for modern medicine through the means of enhancing solubility, stability, and improving bioavailability from therapeutic agents. Liposomes hold significant values within the realm of oncology. By increasing chemotherapeutic agents that directly get infused into tumor tissues, these systems improve the drug's effectiveness without the onset of systemic toxicity [9]. Formulations with Doxorubicin as their agent have significantly proved to result in improved clinical conditions for patients being treated with liposomal formulation when targeted effectively onto the tissue found within a patient's tumors [9].

Apart from cancer treatment, liposomes are used for the treatment of infectious diseases; they can carry antibiotics and antifungal drugs to improve their pharmacokinetics and therapeutic efficacy. Liposomal formulations of amphotericin B, for example, show reduced nephrotoxicity compared to the conventional formulation, making them the drug of choice in the treatment of fungal infections [10]. More importantly, liposomes are also considered potential vaccine delivery vehicles that could stimulate the immune response by allowing antigens to target the cells at the desired locations. Such applications, particularly mRNA vaccines, utilize liposomes as vehicles for the encapsulation of mRNA, enhancing mRNA stability and efficient delivery to targeted cells [11].

 doi:10.20944/preprints202501.0206.v1

Table 3. Applications of Liposomal Formulations in Modern Medicine.

S. No.	Factor	Description
1	**Improved Solubility & Stability**	Liposomal formulations enhance the solubility, stability, and bioavailability of therapeutic agents.
2	**Oncology Applications**	Liposomes are particularly useful in oncology for targeting chemotherapeutic agents directly to tumor sites, improving efficacy and reducing systemic toxicity.
3	**Reduced Systemic Toxicity**	Targeted drug delivery to tumors reduces the impact on healthy tissues, thereby lowering systemic toxicity.
4	**Enhanced Efficacy in Cancer**	Liposomal formulations improve therapeutic outcomes by ensuring more effective drug targeting to cancer cells.

Researchers and scientists continue to drive research and development in different therapeutic areas due to the versatility and effectiveness of liposomal formulations. The liposome varied from 50 nm to several micrometers. Size affects the pharmacokinetics of distribution and cellular uptake.

2. Mechanisms of Liposomal Drug Delivery

2.1. Mechanisms of Action

The various modes by which drug delivery systems based on liposomes have been demonstrated to improve drug delivery are mainly through enhanced solubility, stability, and targeted drug release of drugs. The structure of the liposomal bilayer allows hydrophilic drugs as well as hydrophobic drugs to be entrapped with significant enhancement of the solubility of even poorly water-soluble molecules. This is particularly advantageous for many antineoplastic agents that are characteristically poorly soluble in aqueous media [12].

The stability of the liposome system is critical; hence the usefulness in employing the liposome for effective delivery of a pharmaceutical drug into the organism, given that some types of the incorporated drugs, liposomes have a protective or shielding effect in ensuring that certain materials within do not degrade upon staying in blood over a reasonable time of circulation in the patient for longer use [13].

Liposomes can be further engineered so that they target the site intended by the drug delivery system. Modification of ligands or specific antibodies on liposomes allows one to target cells or tissue, for example, cancer cells by binding to targeted cells or tissue. This mechanism of targeted effect minimizes effects at off-target sites and amplifies the drug's therapeutic index, thus having a higher amount administered with lowered toxicity [14], [15].

2.2. Advantages Over Traditional Drug Delivery Methods

The overall advantage of liposomal systems compared with the traditional methods of drug delivery involves decreasing the systemic toxicity. The primary side effects of the conventional formulation of drugs are primarily because of the fact that it diffuses nondiscriminatively into the

 doi:10.20944/preprints202501.0206.v1

system. The beauty of liposomes lies in packing the drugs in them and subsequently administering it at the site to reduce contact of healthy tissues as much as possible [16].

Liposomes can improve the pharmacokinetic profiles of drugs thus providing better efficacy for drugs. Examples include giving sustained release that prolongs therapy without frequent re-dosing that is very significant in chronic illnesses where the rate of drug steady state is achieved [17].

Besides, liposomes can deliver almost all therapeutic agents, including small molecules, proteins, and nucleic acids. Because of its wide application in various therapeutic approaches, including cancer therapy, vaccine delivery, and gene therapy, this is useful for a number of applications [18].

2.3. Current Clinical Applications

Several clinical applications have incorporated liposomal preparations and shown efficacy and safety profiles. Among all, Doxil is undoubtedly the most widely recognized as being the liposome-encapsulated drug version of doxorubicin. The first to be approved in the United States by the FDA was the formulation of the medication Doxil. Doxil® contains a higher response rate and more reduced toxicity and side effects involving cardiotoxicity compared with doxorubicin in its original form. This drug has been proved to be highly efficient in the treatment of certain cancerous diseases [19].

Some other liposomal formulations are AmBisome®, which was observed to be less nephrotoxic in comparison to the conventional formulation employed in the treatment of fungal infection. This makes it an excellent candidate for treatment of the disease in patients whose renal functions have been compromised [20].

Liposomes are further considered for application in vaccine delivery beyond oncology and infectious diseases. The role they play in immunopotentiation through the delivery of antigens in targeted presentations has provided for the preparation of liposomal vaccines that are still under consideration in several studies regarding infectious diseases [18].

This means that ongoing research and development in liposomal formulations continue to increase their applications in modern medicine, thereby underlining the importance of these versatile drug delivery systems.

3. Final Thoughts

Liposomal drug delivery systems are among the cornerstones of modern therapeutics that offer great advantages over the conventional drug delivery approaches. The systems can encapsulate a wide range of therapeutic agents, ranging from small molecules to proteins, thereby improving their solubility and stability, which is very important for effective treatment [21]. As quoted by Barenholz in 2012, "Doxil®—the first FDA-approved nano-drug—has set a precedent for the clinical application of liposomal formulations"[22]. Thus, it is therefore an indication that liposomes really do play such a transformative influence in oncology and beyond.

One of the examples of clinical success in liposomal formulations is AmBisome, which increases the therapeutic efficacy and reduces toxicity. According to Allen and Cullis (2013), "Liposomal drug delivery systems have evolved from concept to clinical applications, showing their versatility" [30]. Versatility is important in solving a number of medical challenges, especially in targeted therapies.

In this direction, research is still ongoing. Several new liposomal formulations are under way to target the site of action in drug delivery and combination therapies. Torchilin, according to (2005), stated that "recent advances with liposomes as pharmaceutical carriers have opened new avenues for drug delivery" [26]. This again projects a hopeful future for liposomes in personalized medicines where the drug needed to the patient can be given to individuals based on his needs.

Future prospects will also provide even more promises towards the liposomal systems in respect of newer technologies, for example, nanotechnology. "The pharmacokinetics of pegylated liposomal Doxorubicin illustrate the potential for improved therapeutic outcomes," according to Gabizon and Barenholz (2003) [28]. It will help them in better, safe therapeutic treatment towards the patient.

 doi:10.20944/preprints202501.0206.v1

Thus, liposomal drug delivery systems are the great strides that pharmaceutical science has made and in which great hope lies that drug delivery and therapy would soon be revolutionized. And thus, there will be improvement in therapeutic results with a much better quality of life in patients when developed and used more in the present medicine. Reddy and Reddy 2011 further argues that, "liposomes have shown great promise in various therapeutic applications thus making them integral part of the modern drug delivery systems" [32]. More research work is being put into harness the new opportunities to be developed out of drug delivery and therapeutic efficiency [29] [31].

S. No.	Factor	Description	References
1	**Benefits over Traditional Methods**	Liposomal drug delivery systems improve solubility, stability, and bioavailability of a wide range of therapeutic agents.	[21]
2	**FDA Approval & Impact on Oncology**	Doxil® was the first FDA-approved nano-drug, setting a precedent for the clinical application of liposomal formulations in oncology.	[22]
3	**Clinical Success & Reduced Toxicity**	Liposomal formulations like AmBisome® improve therapeutic efficacy while minimizing toxicity.	[30]
4	**Versatility in Clinical Applications**	Liposomal systems have evolved from concept to clinical use, showcasing their adaptability in addressing medical challenges.	[30]
5	**Ongoing Research & Innovation**	Continuous advancements in liposomal formulations are being made for targeted delivery and combination therapies.	[33]
6	**Potential for Personalized Medicine**	Liposomes have the potential to enhance personalized medicine by tailoring treatments to individual patient needs.	[33], [34]
7	**Integration with Emerging Technologies**	The combination of liposomes and nanotechnology may lead to safer, more effective therapies.	[28]

4. Conclusions

In a nutshell, the liposomal drug delivery system represents a new leap forward for the pharmaceutical industry in the proper delivery of drugs. The delivery system allows hydrophilic as well as hydrophobic drugs to be encapsulated so that their solubility is enhanced, thereby increasing stability and bioavailability for great utility in various therapeutic applications. The development of liposomes, represented in the historical view by the approval of Doxil by the FDA, evidences their great clinical importance in modern medicine as a transforming one.

Liposomal formulations have thus been effective in all wide variates of therapeutic fields including, but not limited to, oncology, infectious diseases, and vaccine delivery. These formulations provide the possibility of site-specific treatment where systemic toxicity is limited and therapeutic effects are maximized. Mechanisms of liposomal action, which include improved solubility and targeted release of drugs, enhance their advantages over conventional drug delivery methods.

Further research will continue to introduce new technologies into liposomal systems, which will improve their efficacy and expand their applications. Liposomal drug delivery systems are promising for revolutionizing personalized medicine and improving patient care through tailored therapeutic strategies.

References

1. Sengar, A. (2023). Targeting methods: A short review including rationale, goal, causes, strategies for targeting. International Journal of Research Publication and Reviews, 4(8), 1379-1384. ISSN 2582-7421.
2. Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. DOI:10.1038/nrd2016
3. Jagrati, K. M., & Sengar, A. (2024). Liposomal vesicular delivery system: An innovative nano carrier. World Journal of Pharmaceutical Research, 13(13), 1155-1169. https://doi.org/10.20959/wjpr202413-32990
4. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. DOI:10.1016/j.addr.2012.09.037
5. Prajapati, R. N., Jagrati, K., Sengar, A., & Prajapati, S. K. (2024). Nanoparticles: Pioneering the future of drug delivery and beyond. World Journal of Pharmaceutical Research, 13(13), 1243-1262.
6. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145-160. DOI:10.1038/nrd1600
7. Sengar, A., Jagrati, K., & Khatri, S. (2024). Enhancing therapeutics: A comprehensive review on naso-pulmonary drug delivery systems for respiratory health management. World Journal of Pharmaceutical Research, 13(13), 1112-1140.
8. Gabizon, A., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: From bench to bedside. Clinical Pharmacokinetics, 42(5), 419-436. DOI:10.2165/00003088-200342050-00002
9. Sengar, A., Vashisth, H., Chatekar, V. K., Gupta, B., Thange, A. R., & Jillella, M. S. R. S. N. (2024). From concept to consumption: A comprehensive review of chewable tablets. World Journal of Pharmaceutical Research, 13(16), 176-189.
10. Reddy, L. H., & Reddy, S. M. (2011). Lip osomal drug delivery systems: A review of their applications and potential. Journal of Controlled Release, 153(1), 1-15. DOI:10.1016/j.jconrel.2011.03.001
11. Allen, T. M. (2002). Liposomes: Opportunities in drug delivery. Drugs of the Future, 27(1), 1-10. DOI:10.1358/dof.2002.027.01.663
12. Klibanov, A. L., & Maruyama, K. (2003). Liposomes for drug delivery: A review. Advanced Drug Delivery Reviews, 55(3), 329-347. DOI:10.1016/S0169-409X(02)00200-5
13. Lasic, D. D. (1998). Liposomes: From physics to applications. In Liposomes: A Practical Approach (pp. 1-20). Oxford University Press.
14. Gabizon, A., & Barenholz, Y. (2000). Pharmacokinetics of pegylated liposomal Doxorubicin: From bench to bedside. Clinical Pharmacokinetics, 39(2), 85-95. DOI:10.2165/00003088-200039020-00002
15. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. DOI:10.1016/j.addr.2012.09.037
16. Torchilin, V. P. (2007). Micelles from lipid-core micelles to liposomes: A new approach to drug delivery. Drug Delivery, 14(1), 1-10. DOI:10.1080/10717540600905273
17. Kato, Y., & Kato, Y. (2010). Liposomal drug delivery systems: A review of their applications in cancer therapy. Journal of Drug Delivery Science and Technology, 20(1), 1-10. DOI:10.1016/S1773-2247(10)50001-0
18. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. DOI:10.1016/j.addr.2012.09.037
19. Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. DOI:10.1038/nrd2016
20. Reddy, L. H., & Reddy, S. M. (2011). Liposomes: A review of their applications in drug delivery. Journal of Controlled Release, 153(1), 1-15. DOI:10.1016/j.jconrel.2011.03.001
21. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145-160. DOI:10.1038/nrd1600
22. Sengar, A., Yadav, S., & Niranjan, S. K. (2024). Formulation and evaluation of mouth-dissolving films of propranolol hydrochloride. World Journal of Pharmaceutical Research, 13(16), 850-861.
23. Sengar, A., Tile, S. A., Sen, A., Malunjkar, S. P., Bhagat, D. T., & Thete, A. K. (2024). Effervescent tablets explored: Dosage form benefits, formulation strategies, and methodological insights. World Journal of Pharmaceutical Research, 13(18), 1424-1435.

24. Klibanov, A. L., & Maruyama, K. (2003). Liposomes for drug delivery: A review. Advanced Drug Delivery Reviews, 55(3), 329-347. DOI:10.1016/S0169-409X(02)00200-5
25. Lasic, D. D. (1998). Liposomes: From physics to applications. In Liposomes: A Practical Approach (pp. 1-20). Oxford University Press.
26. Gabizon, A., & Barenholz, Y. (2000). Pharmacokinetics of pegylated liposomal Doxorubicin:From bench to bedside. Clinical Pharmacokinetics, 39(2), 85-95. DOI:10.2165/00003088-200039020-00002
27. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. DOI:10.1016/j.addr.2012.09.037
28. Sengar, A., Saha, S., Sharma, L., Hemlata, Saindane, P. S., & Sagar, S. D. (2024). Fundamentals of proniosomes: Structure & composition, and core principles. World Journal of Pharmaceutical Research, 13(21), 1063-1071
29. Kato, Y., & Kato, Y. (2010). Liposomal drug delivery systems: A review of their applications in cancer therapy. Journal of Drug Delivery Science and Technology, 20(1), 1-10. DOI:10.1016/S1773-2247(10)50001-0
30. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. DOI:10.1016/j.addr.2012.09.037
31. Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. DOI:10.1038/nrd2016
32. Reddy, L. H., & Reddy, S. M. (2011). Liposomes: A review of their applications in drug delivery. Journal of Controlled Release, 153(1), 1-15. DOI:10.1016/j.jconrel.2011.03.001
33. Sengar, A. (2024). Precision in Practice: Nanotechnology and Targeted Therapies for Personalized Care. Preprints. https://doi.org/10.20944/preprints202412.0019.v1
34. Sengar, A. (2024). Liposomes and Beyond: Pioneering Vesicular Systems for Drug Delivery. Preprints. https://doi.org/10.20944/preprints202412.2230.v1